BioNexus Gene Lab Corp. Provision for Other Credit Losses
BioNexus Gene Lab Corp. (BGLC) reported Provision for Other Credit Losses of $118.13 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForOtherCreditLosses · last filed 2026-08-14
- BioNexus Gene Lab Corp. provision for other credit losses for the quarter ending 2025-03-31 was -$25.15K.
- BioNexus Gene Lab Corp. provision for other credit losses for the quarter ending 2024-12-31 was -$2.53M.
- BioNexus Gene Lab Corp. provision for other credit losses for the quarter ending 2024-09-30 was $257.99K.
- BioNexus Gene Lab Corp. provision for other credit losses for the quarter ending 2024-06-30 was $616.17K.
- BioNexus Gene Lab Corp. provision for other credit losses for fiscal 2024 was -$1.69M.
- BioNexus Gene Lab Corp. provision for other credit losses for fiscal 2023 was $0.00.
| Period end | Provision for Other Credit Losses 3 month | Provision for Other Credit Losses 6 month | Provision for Other Credit Losses 9 month | Provision for Other Credit Losses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $118.13K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $97.20K 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$25.15K 10-Q · filed 2025-05-15 | -$2.56M derived: sum of 2 quarters · filed 2025-05-15 | -$2.30M derived: sum of 3 quarters · filed 2025-05-15 | -$1.68M derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | -$2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$2.27M derived: sum of 2 quarters · filed 2025-04-15 | -$1.66M derived: sum of 3 quarters · filed 2025-04-15 | -$1.69M 10-K · filed 2025-04-15 |
| 2024-09-30 | $257.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $874.15K derived: sum of 2 quarters · filed 2024-11-15 | $842.40K 10-Q · filed 2024-11-15 | $842.40K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | $616.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $584.41K 10-Q · filed 2024-08-14 | $584.41K derived: sum of 3 quarters · filed 2025-05-15 | $584.41K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | -$31.75K 10-Q · filed 2025-05-15 | -$31.75K derived: sum of 2 quarters · filed 2025-05-15 | -$31.75K derived: sum of 3 quarters · filed 2025-05-15 | -$31.75K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $0.00 derived: sum of 2 quarters · filed 2025-04-15 | $0.00 derived: sum of 3 quarters · filed 2025-04-15 | $0.00 10-K · filed 2025-04-15 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $0.00 derived: sum of 2 quarters · filed 2024-11-15 | $0.00 10-Q · filed 2024-11-15 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |